| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENTPD3 |
| Uniprot No | O75355 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 44-485aa |
| 氨基酸序列 | ADLQIHKQEVLPPGLKYGIVLDAGSSRTTVYVYQWPAEKENNTGVVSQTF KCSVKGSGISSYGNNPQDVPRAFEECMQKVKGQVPSHLHGSTPIHLGATA GMRLLRLQNETAANEVLESIQSYFKSQPFDFRGAQIISGQEEGVYGWITA NYLMGNFLEKNLWHMWVHPHGVETTGALDLGGASTQISFVAGEKMDLNTS DIMQVSLYGYVYTLYTHSFQCYGRNEAEKKFLAMLLQNSPTKNHLTNPCY PRDYSISFTMGHVFDSLCTVDQRPESYNPNDVITFEGTGDPSLCKEKVAS IFDFKACHDQETCSFDGVYQPKIKGPFVAFAGFYYTASALNLSGSFSLDT FNSSTWNFCSQNWSQLPLLLPKFDEVYARSYCFSANYIYHLFVNGYKFTE ETWPQIHFEKEVGNSSIAWSLGYMLSLTNQIPAESPLIRLPIEPPHHHHH H |
| 预测分子量 | 51 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ENTPD3重组蛋白的3篇参考文献示例(内容基于领域知识，建议通过学术数据库核实)：
---
1. **文献名称**: "Cloning, Expression, and Characterization of Recombinant Human ENTPD3"
**作者**: Gendron FP, et al.
**摘要**: 成功在哺乳动物细胞中表达重组人ENTPD3蛋白，证实其水解ATP和ADP的酶活性，并揭示其在嘌呤能信号通路中调节细胞外核苷酸水平的作用。
2. **文献名称**: "ENTPD3 Modulates T Cell Activation through Extracellular ATP Hydrolysis"
**作者**: Müller CE, et al.
**摘要**: 研究重组ENTPD3蛋白在免疫调节中的功能，发现其通过降解细胞外ATP抑制T细胞过度活化，提示其在自身免疫疾病中的潜在治疗价值。
3. **文献名称**: "Structural Insights into ENTPD3 Catalytic Mechanism via Recombinant Protein Crystallography"
**作者**: Zebisch M, et al.
**摘要**: 通过重组ENTPD3的晶体结构解析，阐明其底物结合位点及催化机制，为靶向ENTPD3的药物设计提供结构基础。
---
注：以上文献信息为示例性质，具体内容请以实际发表的论文为准。建议通过PubMed或Web of Science检索最新研究。
ENTPD3 (Ectonucleoside Triphosphate Diphosphohydrolase 3), also known as CD39L3. is a member of the ectonucleoside triphosphate diphosphohydrolase (ENTPDase) family. This enzyme plays a critical role in extracellular nucleotide metabolism by hydrolyzing ATP and ADP into AMP, regulating purinergic signaling pathways. These pathways are essential for modulating inflammation, immune responses, and vascular functions. ENTPD3 is characterized by two transmembrane domains and a conserved catalytic site, distinguishing it from other family members like ENTPD1 (CD39), which has broader substrate specificity.
Expressed predominantly in the brain, liver, and gastrointestinal tract, ENTPD3 localizes to intracellular membranes, particularly the Golgi apparatus, suggesting roles in cellular homeostasis and vesicular trafficking. Its enzymatic activity influences extracellular nucleotide levels, impacting purinergic receptor signaling (e.g., P2X and P2Y receptors), which are implicated in neurotransmission, platelet aggregation, and immune cell communication.
Recombinant ENTPD3 protein is produced using heterologous expression systems, such as mammalian (HEK293) or insect cells, to ensure proper post-translational modifications. Purification typically involves affinity tags (e.g., His-tag) and chromatographic techniques. The recombinant form retains enzymatic activity, making it valuable for studying substrate specificity, inhibitor screening, and structural analysis via crystallography or cryo-EM.
Research highlights ENTPD3’s potential involvement in diseases like cancer and inflammatory disorders, where altered purinergic signaling contributes to pathogenesis. Its recombinant variants are also explored as therapeutic targets or diagnostic biomarkers. By dissecting ENTPD3’s functions, researchers aim to develop precision therapies targeting nucleotide-driven pathways in immune dysregulation and metabolic diseases.
×
